Clinical Trial Update: Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A dose-escalation Phase I/II trial evaluating Lutetium-177-labeled cG250 for advanced/metastatic renal cell carcinoma has completed enrollment with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Lutetium-177-labeled cG250 (Lutetium-177-labeled cG250)

Snippet

Sponsor: Ludwig Institute for Cancer Research | Conditions: Metastatic Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-03-22